AI assistant
ABBOTT LABORATORIES — Director's Dealing 2017
Jul 26, 2017
29777_dirs_2017-07-26_9dbe6975-c8a2-4d7e-a7e8-4a0d618f4dac.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2017-07-24
Reporting Person: BRYNELSEN CHARLES (Senior Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-07-24 | Common shares without par value | A | 9980 | — | Acquired | 9980 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-07-24 | Option (right to buy) | $50.74 | A | 69024 | Acquired | 2027-07-23 | Common shares (69024) | Direct |
Footnotes
F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,008 on 07/24/2018, 23,008 on 07/24/2019, and 23,008 on 07/24/2020.